Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension
To compare the effect of megestrol acetate concentrated suspension and placebo on caloric intake in patients with cancer-associated anorexia.
Anorexia|Cachexia|Weight Loss
DRUG: Megestrol acetate concentrated suspension 110 mg/mL|DRUG: Megestrol acetate concentrated suspension 60 mg/mL|DRUG: Placebo
Average Daily Caloric Intake Over the Course of the 8-week Double-blind Phase, The Nutrition Data System for Research (NDSR) was used to determine nutrient and caloric value for foods and beverages consumed and recorded by subjects over a 3-day assessment period prior to each visit. Total number of calories consumed during each 3-day assessment was averaged over available values to determine the week's daily caloric intake value., 8 weeks
Change in Weight Over the Course of the 8-week Double-blind Phase, Baseline, Week 1, 2, 3, 4, 6, and 8|Changes in Body Composition as Measured by Bioelectric Impedance Analysis (BIA) at Week 4 and Week 8 Relative to Baseline, Baseline, Week 4 and Week 8|Change in Appetite Over the 8-week Double-blind Phase as Measured by a VAS Appetite Scale, Subjects marked 6 items on a visual analog scale (VAS) appetite scale including feeling not hungry to hungry, not nauseated to nauseated, empty to full, not satiated to satiated; weak to strong desire to eat; and ability to eat none to a large amount of food, Baseline, Weeks 1, 2, 3, 4, 6 and 8
To compare the effect of megestrol acetate concentrated suspension and placebo on caloric intake in patients with cancer-associated anorexia.